Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CTO0101 Eye Drops in Healthy Adults
NCT05262179Phase 1Unknown
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Start
- Oct 2021
- Primary completion
- May 2022
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in post-operative ocular inflammation and Bacterial ocular infection comparing CTO0101 with Placebo (2 arms). Primary endpoints: Maximum Plasma Concentration at Steady State, Time to Maximum Plasma Concentration at Steady State and 3 more. Status: unknown.
02
Drugs
CTO-0101
03
Conditions
post-operative ocular inflammationBacterial ocular infection
Beyond the preview
Go deeper on NCT05262179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262179.